Please login to the form below

insulin degludec

This page shows the latest insulin degludec news and features for those working in and with pharma, biotech and healthcare.

Novo Nordisk fends off Lilly’s GLP-1 challenge in Q1

Novo Nordisk fends off Lilly’ s GLP-1 challenge in Q1. Insulin specialist bounces back with encouraging signs from Ozempic launch. ... This was despite growth for new long-acting insulin Tresiba (insulin degludec), which grew 33% to DKK 1.75bn in local

Latest news

CHMP backs first-line use for AZ’s Tagrisso in lung cancer

insulin degludec/liraglutide).
Sanofi wins EU approval for new diabetes combination Suliqua

The dual-drug treatment combines the firm's blockbuster Lantus (insulin glargine) and with Lyxumia (lixisenatide) and aims to improve glycaemic control for those where metformin alone or in combination is ... same day as rival therapy Xultophy, Novo
Sanofi launches insulin combo Soliqua in US

Sanofi launches insulin combo Soliqua in US. Diabetes drug available in pharmacies for $127 per 300 unit pen ahead of Novo Nordisk's Xultophy. ... Soliqua (insulin glargine/lixisenatide) reaches the market ahead of Novo Nordisk's rival combination
FDA clears rival diabetes combos from Sanofi and Novo Nordisk

day. Both products include a long-acting basal insulin coupled with a GLP-1 agonist and are intended for the treatment of patients with type 2 diabetes who are not managing ... In the case of Xultophy, the combination is based on Novo's basal insulin
Novo Nordisk to cut 1,000 jobs as diabetes competition builds

momentum for its new basal insulin product Tresiba (insulin degludec). ... 1bn (2.86bn) brought in by Sanofi's established blockbuster Lantus (insulin glargine) during the same period.

More from news
Approximately 13 fully matching, plus 58 partially matching documents found.

Latest Intelligence

Interview: Peter Meeus, Novo Nordisk

Vice president sales and marketing, Novo Nordisk. International marketing manager insulin analogues, Novo Nordisk. ... Not reporting it is a very big issue.”. Novo has attempted to address hypoglycaemia with the launch of its new insulin Tresiba

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Scientific Communications Director - Oncology – In House Pharma ...: Neg

Principal Medical Writer / Editorial Director – Medical Communic...: £60, 000 - £80, 000

Home based, Chief Medical Writer, Medical Communications: Excellent package

Client Services Director - Med Comms: Great salary and bebefits

Client Services Director – Healthcare Advertising - London: Neg

Account Director, Consumer Healthcare PR, Global PR agency: £50, 000 – £58, 000

Home based, Editorial Team Leader, Medical Communications: Excellent package

Account Manager: £40, 000 - £45, 000 benefits

Senior Project Manager - Medical Writing: Great salary and bebefits

Business Unit Head, Medical Communications, London: Excellent package

Senior Account Manager: Competitive salary commensurate with experience

Editorial Director – Medical Education (MedComms): Neg

Home based, Principal Medical Writer, Medical Communications: Excellent package

Home based, Senior Medical Writer, Medical Communications: Excellent package

Delivery Manager/ Head of Delivery – Executive Search: Neg

Strategic Planner, Healthcare Advertising: £47, 000 – £53, 000

Head of Market Access - International - Based Cambridge: Excellent Basic, Bonus and Flex Benefits

Account Director, Medical Communications: C£50 – 65, 000 benefits and bonus

Senior Medical Writer, Healthcare Advertising Agency: £45, 000 – £50, 000

Multi-Channel Account Managers - Road / Homebased – Full or Part...: Competitive salary

Subscribe to our email news alerts

PMHub

Add my company

Syneos Health™

Syneos Health™ is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract...

Latest intelligence

Digital trends in B2B sales - how far behind is Pharma?: The modern approach to B2B sales is data-driven, and enabled by digital tools....
The rise of vertical integration in the US payer landscape: Is it a solution to addressing the challenges of the value-based marketplace?...
Creativity has lost its worth: Creativity has lost its worth, and sadly it is undermining effectiveness...